Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer

Tianjin Medical University

Status and phase

Not yet enrolling

Phase 2

Conditions

Gastric Cancer

Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma

Treatments

Drug: Sintilimab + Fruquinitinib + S-1 plus nab-paclitaxel

Drug: Sintilimab + S-1 plus nab-paclitaxel

Study type

Interventional

Funder types

Other

Identifiers

NCT06454435

E20231573

Details and patient eligibility

About

This is a multicenter, randomized, open-label, phase 2 clinical study aiming to evaluate the feasibility and efficacy of sintilimab (PD-1 inhibitor) in combination of fruquintinib and chemotherapy (S-1 plus nab-paclitaxel) versus sintilimab and chemotherapy as conversion therapy in patients with stage IV gastric cancer in China.

Enrollment

158 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Histologically confirmed gastric/gastroesophageal junction adenocarcinoma through gastroscopy.
Ages: 18-70 Years (concluding 18 and 70 Years)
Life expectancy ≥3 months.
Treatment-naive Stage IV (clinical staging, AJCC 8th) unresectable patients, no prior antitumor therapy (including radiation, chemotherapy, targeted therapy or immunotherapy, etc.).
The Eastern Cooperative Oncology Group Performance status (ECOG PS) of 0-1.
Preoperative examinations using CT, MRI, PET-CT, etc., indicating only one unresectable factor OR peritoneal metastasis with another unresectable factor, such as:
1. N3 lymph node metastasis, mainly referring to group 16 lymph node metastasis.
2. Extensive or bulky lymph nodes (D2)
3. Locally advanced T4b.
4. Hepatic metastases (H1): ≤5 lesions with a total diameter ≤8cm.
5. Peritoneal metastasis (CY1, P1).
6. Ovarian metastasis (Krukenberg tumor).
Physically fit for major abdominal surgery.
Adequate organ and marrow function, defined as:
1. Hematological status: Absolute neutrophil count (ANC) ≥1.5×10^9/L; Platelet count (PLT) ≥100×10^9/L; Hemoglobin (HGB) ≥9.0 g/dL.
2. Liver function: For patients without liver metastasis, serum total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN); ALT and AST ≤2.5×ULN. For patients with liver metastasis: TBIL ≤1.5×ULN; ALT and AST ≤5×ULN.
3. Renal function: Creatinine clearance (Ccr) ≥50 mL/min (calculated using the Cockcroft/Gault formula).
Adequate coagulation function, defined as International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 times ULN.
Voluntary participation and signed informed consent with expected good compliance and follow-up.
Not involved in other clinical trials.
Willing to provide blood and histological samples.
No serious conditions affecting anesthesia, or surgery.
No hematologic disorders affecting postoperative hemoglobin levels.

Exclusion criteria

Has distal metastases other than oligometastases as defined in the inclusion criteria, such as pulmonary metastases, brain metastases, bone metastases, etc.
HER-2 positive patients or willing to receive Trastuzumab.
Endoscopic signs of active bleeding from the lesion.
Patients with moderate/large volume of ascites.
Near-obstruction at the cardia or pylorus affecting feeding and gastric emptying or difficulty swallowing tablets.
Concurrently suffering from other serious illnesses that are difficult to control (Severe uncontrolled recurrent infections, atrial fibrillation, angina pectoris, cardiac insufficiency, ejection fraction measurement under 50%, uncontrolled hypertension, renal insufficiency, symptomatic peripheral neuropathy, and NCI classification >II)
Has already on other medications prior to enrollment or could not be assured of compliance after enrollment.
Allergy to any drugs in the regimen.
Women who are pregnant or breastfeeding and have childbearing potential but are not taking adequate contraceptive measures.
Organ transplant recipients requiring immunosuppression.
Patients without decision-making capacity or with psychiatric disorders.
Systemic treatment with Chinese herbal anti-tumor or immunomodulatory drugs (including thymosin, interferons, interleukins) within 2 weeks before the first dose.
Use of immunosuppressive drugs within 4 weeks before the first study treatment, excluding local steroids or physiological doses of systemic steroids.
Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study treatment.
Has a diagnosis of autoimmune disease within the previous 2 years (Patients with vitiligo, psoriasis, alopecia areata, or Graves' disease who do not require systemic therapy within the last 2 years, hypothyroidism requiring only thyroid hormone replacement therapy, and type I diabetes mellitus requiring only insulin replacement therapy are eligible for enrollment).
Known history of primary immunodeficiency.
Known to have active tuberculosis.
Has history of human immunodeficiency virus (HIV) infection (i.e., HIV antibody . positive); untreated acute or chronic active hepatitis B or hepatitis C infection. Patients receiving antiretroviral therapy are eligible for enrollment on an individual basis as determined by the physician with monitoring of viral copy number.
Urinalysis indicating urine protein ≥2+ and 24-hour urine protein quantification >1.0g.